PTPIOTCPharmaceutical PreparationsFiscal year ends December 31
Petros Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.00+0.00 (+5.56%)
Close on Oct 19, 2026
- Market cap
- $135.07K
- P/E (TTM)
- –
- Dividend yield
- –
Petros Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Petros Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $120.76K | $164.85M |
| Enterprise Value | -$3.37M | $87.06M |
| PB Ratio | 0.17 | 2.03 |
| P/TBV Ratio | 0.17 | 2.31 |
Income (trailing twelve months)
| Measure | Petros Pharmaceuticals | Industry median |
|---|---|---|
| Operating Income | -$3.40M | -$21.44M |
| Pretax Income | -$3.20M | -$14.45M |
| Net Income | -$3.20M | -$22.46M |
| EBITDA | -$3.40M | -$16.91M |
Returns
| Measure | Petros Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -124.4% | -53.1% |
| Return on Assets (ROA) | -58.5% | -41.0% |
| Return on Capital Employed (ROCE) | -484.8% | -37.8% |
Balance sheet
| Measure | Petros Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $3.49M | $62.42M |
| Net Cash (Debt) | $3.49M | $15.68M |
| Net Cash Per Share | $0.08 | $0.66 |
| Equity (Book Value) | $700.89K | $48.79M |
| Book Value Per Share | $0.02 | $1.36 |
| Tangible Book Value | $700.89K | $23.06M |
| Working Capital | $700.89K | $75.77M |
Financial position
| Measure | Petros Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 1.25 | 3.30 |
| Quick Ratio | 1.23 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Petros Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$3.72M | -$12.35M |
Efficiency
| Measure | Petros Pharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | -$1.07M | -$703.34K |
| Employee Count | 3 | 74 |
Dividends and yields
| Measure | Petros Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -2651.4% | -22.7% |
Shares
| Measure | Petros Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 42,372,300 | 58,179,650 |
| Shares Change (YoY) | 539.6% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 27,256,800 | 49,173,100 |
| Shares Held by Insiders | 35.7% | 11.6% |
Scores
| Measure | Petros Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -47.61 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Petros Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.